Cardiovascular risk factors in Type 2 diabetes: the role of hyperglycaemia

被引:27
作者
Massi-Benedetti, M [1 ]
Federici, MO [1 ]
机构
[1] Univ Perugia, Dept Internal Med, I-06100 Perugia, Italy
关键词
Type; 2; diabetes; cardiovascular risk factors; macrovascular complications; hyperglycaemia;
D O I
10.1055/s-0029-1212165
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Macrovascular complications are the most important causes of morbidity, mortality and disability in people with Type 2 diabetes mellitus. Although other known risk factors for macrovascular disease (e.g, dyslipidaemia, hypertension, obesity) often co-exist, diabetes itself is an important risk factor for accelerated development of atherosclerosis. Hyperglycaemia, hyperinsulinaemia and insulin resistance may each play a major role in the onset and development of atherosclerotic disease, which causes arterial wall dysfunction, haematological disturbances and lipid abnormalities through two mechanisms: oxidative stress and nonenzymatic glycation. Hyperglycaemia induces damage to the endothelium through activation of mitogen-activated protein kinase, protein kinase C and transcription factor nuclear factor (NF)-kappa B and through increased levels of pro-adhesion proteins such as intracellular adhesion molecule (ICAM)-1. The arterial wall tone is shifted towards vasoconstriction by hyperglycaemia, which is also associated with vascular smooth muscle cell proliferation and increased intimal wall thickness. Alteration of the coagulation system towards thrombophilia is observed in Type 2 diabetes and a series of lipid abnormalities that facilitate the development of atherosclerosis is evident. In Type 2 diabetes, undiagnosed disease and unrecognized postprandial hyperglycaemia are becoming the most relevant issues in reducing the risk of vascular complications and cardiovascular mortality; improved glycaemic control may reduce the incidence of macrovascular complications.
引用
收藏
页码:S120 / S123
页数:4
相关论文
共 33 条
[21]   Endothelial dysfunction: Cause of the insulin resistance syndrome [J].
Pinkney, JH ;
Stehouwer, CDA ;
Coppack, SW ;
Yudkin, JS .
DIABETES, 1997, 46 :S9-S13
[22]  
RIM JA, 1994, DIABETES, V43, P1103
[23]   Blood vessel wall interactions in diabetes [J].
Schror, K .
DIABETES, 1997, 46 :S115-S118
[24]  
Seligman BGS, 1998, DIABETES, V47, pA53
[25]   GLUCOSYLATION OF LOW-DENSITY LIPOPROTEINS TO AN EXTENT COMPARABLE TO THAT SEEN IN DIABETES SLOWS THEIR CATABOLISM [J].
STEINBRECHER, UP ;
WITZTUM, JL .
DIABETES, 1984, 33 (02) :130-134
[26]  
Sugimoto H, 1998, DIABETES, V47, pA112
[27]  
Temaru R, 1998, DIABETES, V47, pA112
[28]   10-YEAR CARDIOVASCULAR MORTALITY IN RELATION TO RISK-FACTORS AND ABNORMALITIES IN LIPOPROTEIN COMPOSITION IN TYPE-2 (NON-INSULIN-DEPENDENT) DIABETIC AND NONDIABETIC SUBJECTS [J].
UUSITUPA, MIJ ;
NISKANEN, LK ;
SIITONEN, O ;
VOUTILAINEN, E ;
PYORALA, K .
DIABETOLOGIA, 1993, 36 (11) :1175-1184
[29]   Recent progress in advanced glycation end products and diabetic complications [J].
Vlassara, H .
DIABETES, 1997, 46 :S19-S25
[30]   REDUCED MEMBRANE FLUIDITY IN PLATELETS FROM DIABETIC-PATIENTS [J].
WINOCOUR, PD ;
BRYSZEWSKA, M ;
WATALA, C ;
RAND, ML ;
EPAND, RM ;
KINLOUGHRATHBONE, RL ;
PACKHAM, MA ;
MUSTARD, JF .
DIABETES, 1990, 39 (02) :241-244